Title:
悪性Ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
Document Type and Number:
Japanese Patent JP7089806
Kind Code:
B2
Abstract:
The present invention relates to a new antibody or an antigen binding fragment thereof for use in the treatment of cancer by targeting a B cell malignancy, a chimeric antigen receptor comprising the same, and a use of the same. The antibody of the present invention is an antibody for specifically binding to CD19 that is highly expressed in cancer cells (particularly, blood cancer), has very low homology to a CDR sequence thereof compared to a CDR sequence of a conventional CD19 target antibody so that the sequence thereof is unique, and specifically binds to an epitope that is different from a FMC63 antibody fragment binding to CD19 of the conventional art. A cell expressing the chimeric antigen receptor comprising an anti-CD19 antibody or the antigen binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD19, and thus may be utilized as a CAR-immune cell therapeutic agent.
Inventors:
Lee, Jung Seo
Kim, Gute
Ko, Ponguk
Kim, Ki Hyun
Kim, Gute
Ko, Ponguk
Kim, Ki Hyun
Application Number:
JP2020530356A
Publication Date:
June 23, 2022
Filing Date:
December 06, 2018
Export Citation:
Assignee:
ABCLON INC.
International Classes:
C12N15/13; A61K35/12; A61K39/395; A61P29/00; A61P35/00; A61P37/06; A61P43/00; C07K16/30; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63
Domestic Patent References:
| JP2008546647A | ||||
| JP2016520074A |
Foreign References:
| WO2016139487A1 | ||||
| WO2017066136A2 |
Attorney, Agent or Firm:
Patent business corporation HARAKENZO WORLD PATENT & TRADEMARK
Previous Patent: Electrochemical oxygen reduction catalyst
Next Patent: Diagnosis of stroke through bacterial metagenomics
Next Patent: Diagnosis of stroke through bacterial metagenomics